Lipid-insertion enables targeting functionalization of erythrocyte membrane-cloaked nanoparticles

Summary

This study develops a noncovalent method for adding targeting ligands to red-blood-cell membrane-coated polymeric nanoparticles. Direct chemical conjugation can alter or damage a complex biological membrane, so the investigators inserted lipid-linked targeting molecules into the existing membrane layer instead. They demonstrated the approach with folate and AS1411, an aptamer directed at nucleolin. In model cancer cell lines, each modified carrier showed receptor-specific targeting consistent with its added ligand. The principal result is that lipid insertion can expand the targeting repertoire of a long-circulating biomimetic particle without requiring chemical modification of native membrane proteins. This is significant because it separates two functions: the erythrocyte membrane can provide its baseline circulation and immune-interface properties, while interchangeable lipid-linked ligands add disease recognition. The abstract is brief and supports only an early in vitro proof of concept. It does not report insertion efficiency, ligand density, membrane stability, receptor expression, uptake values, controls beyond specificity, drug cargo, cell-killing efficacy, serum behavior, or whether targeting survives prolonged circulation. No animal biodistribution, tumor delivery, toxicity, immunogenicity, manufacturing reproducibility, or clinical evidence is provided, and only two ligands and model cell lines were tested.